5 251

Cited 8 times in

Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer

Authors
 Seungtaek Lim  ;  Byoung Chul Cho  ;  Ji Ye Jung  ;  Gun Min Kim  ;  Se Hyun Kim  ;  Hye Ryun Kim  ;  Han Sang Kim  ;  Sun Min Lim  ;  Ji Soo Park  ;  Jun Ho Lee  ;  Darae Kim  ;  Eun Young Kim  ;  Moo Suk Park  ;  Young Sam Kim  ;  Se Kyu Kim  ;  Joon Chang  ;  Joo Hang Kim 
Citation
 Lung Cancer, Vol.80(3) : 313-318, 2013 
Journal Title
 Lung Cancer 
ISSN
 0169-5002 
Issue Date
2013
Abstract
The aim of this study was to investigate the efficacy and safety of belotecan in combination with cisplatin in patients with previously non-treated extensive stage small cell lung cancer. A total of 42 patients were enrolled and treated with combination of belotecan 0.5 mg/m2 on daily basis throughout day 1–4 and cisplatin 60 mg/m2 on day 1 of a 3-week cycle, up to 6 cycles. Treatment was continued until the completion of 6 cycles of the chemotherapy, disease progression, detection of unacceptable toxicity, withdrawal of the consent, or death of the patient. Response was assessed every 2 cycles of chemotherapy by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Toxicity was assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0. The overall response rate was 73.8% in an intention to treat population and 83.9% in the evaluable patients. With the median follow up of 9.9 months, the median progression free survival was 6.9 months (95% CI, 6.6–7.2 months), and median overall survival was 11.2 months (95% CI, 9.9–12.5 months). The frequently reported grade ≥ 3 toxicities were neutropenia (90.2%), thrombocytopenia (63.4%), and anemia (34.1%). Febrile neutropenia was reported in 16 patients (39.0%). Although most of non-hematologic toxicities were grade 1 or 2, there were 4 patient deaths caused by pneumonia complicated by septic shock. Belotecan and cisplatin combination chemotherapy demonstrated a promising efficacy in ED SCLC patients. But, the hematologic toxicity of this regimen requires considerable amount of attention.
Full Text
http://www.sciencedirect.com/science/article/pii/S0169500213000688
DOI
10.1016/j.lungcan.2013.02.009
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실)
Yonsei Authors
김건민(Kim, Gun Min) ORCID logo https://orcid.org/0000-0001-9167-8682
김다래(Kim, Da Rae)
김세규(Kim, Se Kyu)
김세현(Kim, Se Hyun)
김영삼(Kim, Young Sam) ORCID logo https://orcid.org/0000-0001-9656-8482
김은영(Kim, Eun Young)
김주항(Kim, Joo Hang)
김한상(Kim, Han Sang) ORCID logo https://orcid.org/0000-0002-6504-9927
김혜련(Kim, Hye Ryun) ORCID logo https://orcid.org/0000-0002-1842-9070
박무석(Park, Moo Suk) ORCID logo https://orcid.org/0000-0003-0820-7615
박지수(Park, Ji Soo)
이준호(Lee, Jun Ho)
임선민(Lim, Sun Min)
임승택(Lim, Seung Taek)
장준(Chang, Joon)
정지예(Jung, Ji Ye) ORCID logo https://orcid.org/0000-0003-1589-4142
조병철(Cho, Byoung Chul)
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/87356
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse